Southern blotting was performed with cDNA probes for the human von Willebrand factor (vWF) gene on six patients with severe type 111 von Willebrand's disease (vWD). A partial deletion in the 3' end of the vWF gene was demonstrated in one individual whose parents were related and who had an alloantibody inhibitor to vWF. A resulting novel 2.0-kilobase (kb) EcoRl fragment was used for carrier detection within the patient's family, and seven carriers of this recessive trait were identified. Of the six tested, five had normal or only slightly reduced levels of vWF antigen, but with generally higher levels of factor VIII. The sixth carrier had moderately severe vWD and it is O N WILLEBRAND'S DISEASE (vWD) is an autoso-V mally inherited heterogeneous condition characterized by qualitative and/or quantitative defects in von Willebrand factor (vWF) in both plasma and platelets. This is often accompanied by reduced levels of factor VI11 (FVIII) and the precise pathogenesis of the condition is at present poorly understood.' The cloning of the vWF gene by several groups2-' has, however, opened up the possibility of defining the condition at the molecular level. The gene has been localized to chromosome 1 2,2,4 but homologous sequences have also been localized to chromosome 22."
Southern blotting was performed with cDNA probes for the human von Willebrand factor (vWF) gene on six patients with severe type 111 von Willebrand's disease (vWD). A partial deletion in the 3' end of the vWF gene was demonstrated in one individual whose parents were related and who had an alloantibody inhibitor to vWF. A resulting novel 2.0-kilobase (kb) EcoRl fragment was used for carrier detection within the patient's family, and seven carriers of this recessive trait were identified. Of the six tested, five had normal or only slightly reduced levels of vWF antigen, but with generally higher levels of factor VIII. The sixth carrier had moderately severe vWD and it is O N WILLEBRAND'S DISEASE (vWD) is an autoso-V mally inherited heterogeneous condition characterized by qualitative and/or quantitative defects in von Willebrand factor (vWF) in both plasma and platelets. This is often accompanied by reduced levels of factor VI11 (FVIII) and the precise pathogenesis of the condition is at present poorly understood.' The cloning of the vWF gene by several groups2-' has, however, opened up the possibility of defining the condition at the molecular level. The gene has been localized to chromosome 1 2,2,4 but homologous sequences have also been localized to chromosome 22."
The most severe form of vWD is characterized by undetectable levels of vWF, vWF antigen (vWFAg), and by greatly reduced levels of FVIII (type 111 vWD). Many of these individuals are thought to be homozygous for a recessive form of vWD and result from consanguineous relationships. A small number of these rare patients also develop inhibitors (antibodies) to vWF as a result of replacement therapy.'' Two reports of DNA analysis with cDNA probes of the vWF gene in this latter condition have indicated probable complete deletions of the vWF In a recent report by Ginsburg et aI,l3 defective vWF messenger R N A (mRNA) transcription or processing was identified in a type I vWD patient, and in two type IIA patients, different point mutations within a short 10-codon segment were observed. These studies were performed on a DNA sequence obtained by use of the polymerase chain reaction (PCR) to amplify mRNA from the patient's platelets. Details of the complete vWF gene structure await publication, although a total of 52 exons are believed to be present (Sadler J.E., unpublished observations). Information on the exon/intron organization of the first five exons at the 5' end of the gene have been reported.' Nine restriction fragment length polymorphisms (RFLP) within the vWF gene have been r e p~r t e d '~.~' and several have been used in family s t~d i e s . '~. ~~ We now report a family with recessive vWD in which the affected vWF gene is partially deleted. The deletion is defined at the gene level and exon 42 is shown to be deleted. The propositus with severe type 111 vWD and an inhibitor to vWF is homozygous for the condition, and the defect is traced to seven members of the kindred who are heterozygous carriers. Six are asymptomatic, but the seventh has moderately severe vWD, and is probably a compound heterozygote for this condition and an as yet unidentified second recessive vWD trait.
MATERIALS AND METHODS

Materials
Agarose, low-melting-point agarose, large-fragment DNA polymerase I, and restriction endonucleases were from BRL Ltd, Paisley, UK. Proteinase K and bovine serum albumin (BSA) were from BCL, Lewes, UK. Triton X-100, phenol, and sodium dodecyl sulphate (SDS) were obtained from BDH Chemicals Ltd, Poole, UK. Salmon sperm DNA, polyvinyl-pyrrolidone (PVP), Ficoll-400, and dextran sulphate were from Sigma Chemical Co, Poole, UK. Hybond-N membrane was purchased from Amersham International, Amersham, UK. Hexadwxyribonucleotides were purchased from Pharmacia Ltd, Milton Keynes, UK, and 32P-labeled deoxyribonucleotides and [35S]dATP S were from DuPont (Stevenage, UK) and Amersham. Ortho G x-ray film and X-Omatic cassettes were obtained from Kodak Ltd, Heme1 Hempstead, UK. All other 
Probes
For the vWD patient studies, a full-length vWF cDNA probe (8.8 kb) was kindly provided by Dr Dennis Lynch, Harvard Medical School, Boston, MA. The insert was excised by digestion with EcoRI/SalI from plasmid pGEM2. A 1.9-kb 3' cDNA probe was obtained from this full-length cDNA by digestion with SacI (Fig 1) . The third probe used was a 1.1-kb PstI fragment (Fig 1) also from the 3' end of the gene and isolated in Amsterdam. All molecular biologic procedures were performed under laboratory conditions as recommended by the UK Advisory Committee on Genetic Manipulation.
Restriction Endonuclease Analysis
Blood was collected into one-tenth volume of 3.8% trisodium citrate and centrifuged at 1,500 x g for 15 minutes. Platelet-poor plasma was aspirated and stored at -2OOC before FVIII and vWF assays (see below). High molecular weight (mol wt) DNA (300 to 500 pg) was extracted from the cellular material according to the method of Kunkel et al." After restriction enzyme digestion of 10 pg of DNA and agarose gel electrophoresis, the DNA fragments were blot-transferred from the gel onto Hybond-N using the method of Southern,26 and they were covalently fixed by wrapping the membrane in plastic wrap and exposing it to short-wavelength UV irradiation. After prehybridization in 6X standard saline citrate (SSC; 1 x SSC is 0.1 5 mol-L NaCl, 0.05 mol-L sodium citrate) and 5X Denhardt's (100 x Denhardt's is 2% wt/vol BSA, 2% wt/vol PVP, 2% wt/vol Ficoll-400, 0.5% SDS, 2Opg/mL heat-denatured salmon sperm DNA, and 10% dextran sulphate), hybridization was performed for 24 to 48 hours in the same solution with the addition of the heat-denatured radioactive probes (1.0 pCi/mL, 5 ng/mL). The DNA probes were radiolabeled, after excision from the plasmid, to a specific activity of up to 5 x lo8 dpm/pg by the oligonucleotide priming method of Feinberg and V~gelstein.~' The membranes were then washed twice in 2 x SSC for 30 minutes at 65OC, followed by two washings in 0.1 x SSC/O.l% SDS for 10 minutes at 65OC. After air drying, the membranes were exposed to x-ray film for 2 to 10 days at -7OOC. For rehybridization, membranes were first incubated in 0.4 mol-L NaOH at 45OC for 30 minutes followed by incubation in 0.1 x SSC/O.l%, SDS/O.2 mol-L Tris, pH 7.5, at 45OC for 30 minutes before repeating the prehybridization protocol. 
Patient Studies
Preparation and Screening of Genomic DNA Libraries and DNA Sequencing
High mol wt DNA was prepared from peripheral blood leukocytes by the method of Kunkel et DNA was partially digested with Sau3A and was then size-selected by centrifugation on a 1.25 mol/L to 5.0 mol/L continuous sodium chloride gradient in Tris/ethylenediamine tetraacetic acid (EDTA) pH 8.0 (10 mmol/L Tris, 1 mmol/L EDTA, 100.000 g for 4 hours). Post centrifugation aliquots from the sample were analyzed on a 0.3% agarose gel with known size markers, and a fraction containing DNA of 30 to 15 kb was identified, ethanol-precipitated, and used to construct a genomic library in phage EMBL3 (Frishauf et aV3) of greater than 2 x lo6 clones. The library was screened by the method of Benton and D a~i e s~~ with the 1.9-kb 3'cDNA probe (Fig 1) . Four positive clones were identified. EcoRI restriction mapping of the genomic DNA inserts of the clones and comparison with the tentative 3' restriction map of the normal vWF gene reported by Verweij et alZ2 confirmed the identity of the clones, with the exception of a novel 2.0-kb fragment that appeared to replace the normal 4.2-kb fragment. This 2.0-kb fragment was subcloned into pGEM Blue (Promega Biotech, Madison, WI) and used as a probe with Southern blots of EcoRI-digested DNA from S1, his carrier relatives (see below), and normal DNA. A single band of either 2.0 kb (patient and carriers) or 4.2 kb was seen, confirming that this clone, JB2000, corresponded to the novel EcoRI fragment seen in the patient's DNA. JB2000 was subcloned into MP18 sequencing vector and the first 500 bp (5') were sequenced. An XbaI restriction enzyme site was detected at this point, and thereafter further sequencing was performed on the 1.5-kb XbaIIEcoRI remaining 3' fragment of the clone. This fragment was subcloned into MP18 and MP19 and nested deletions created by the ExoIII digestion method of Guo and W U ,~~ thus allowing the entire 1.5-kb fragment to be sequenced as a series of overlapping fragments. All sequencing was by the dideoxy chain termination method of Sanger et A human fetal liver genomic DNA library in the bacteriophage X Charon 4A was obtained from Dr Tom Maniatis (Harvard University, Boston, A human leukocyte genomic DNA library in the pTCF cosmid vector was obtained from V. Michael Holers (Howard Hughes Medical Institute, Washington University, St Louis, MO).39 These libraries were screened34 with a 1.8-kb SacI fragment from the 3' end of the human vWF cDNA, referred to as
Screening of the normal human genomic DNA libraries.
probe IV," labeled with '*P-dCTP by nick-translati~n~~ or random oligonucleotide priming" to 10' to IO9 dmplrg. Positive isolates were purified and further characterized by restriction enzyme mapping, blot hybridization, and DNA sequencing. The 4.2-kb EcoRl fragments from isolates X I 1 and cosmid HI8 that contained exons 41 and 42 of the vWF gene were subcloned into plasmid Bluescript KS (Stratagene, La Jolla, CA) for further characterization. DNA fragments subcloned into plasmid vectors were sequenced directly" using Sequenase (United States Biochemical Corporation, Cleveland, OH) and synthetic oligonucleotide primers. Sequencing reactions were performed by the dideoxy method of Sanger et all6 using From the sequence of JB2000 these primers should result in the amplification of a sequence of 246 bp in patient SI and his carrier relatives with thedeleted vWFgene and the 182-bp insertion. In the normal nondeleted vWF gene, a sequence of 2.384 bp would be amplified.
Sequencing and sequence analysis of normal clones.
RESULTS
Screening for Gene Defects by Southern Blotting
DNA from six patients with severe type 111 vWD (vWFAg < 0.01 U/dL) was initially studied by Southern blotting using a full-length vWF gene cDNA probe (Fig 1) . After digestion with EcoRI, a complex pattern of at least 18 fragments was observed (Fig 2, severe vWD SI to S6, normals NI to N3). Abnormal patterns were seen in two cases. S3 showed an extra band at approximately 3.2 kb. We are unsure as to the origin of this band. S1 had a missing band of about 4.2 kb and a novel band at 2.0 kb. The intense band seen at about 3.5 kb in the SI track was not observed in subsequent experiments.
To localize the defect in SI, EcoRI digests were reprobed with the 1.9-kb 3'cDNA probe (Fig 1) . The results indicated that the 4.2-kb band missing in SI and the novel 2.0-kb fragment originated from the 3' end of the gene. This was confirmed by digesting the patient's DNA with a series of restriction enzymes and probing with the 1. probes (Fig I) . Thus, with BglII a normal 5.0-kb fragment was replaced by a novel 6.4-kb fragment, and with Hind111 a 6.9-kb band was lost (results not shown). These results, together with our failure to detect the novel 2.0-kb fragment in 40 normal DNAs digested with EcoRI and probed with the 1.9-kb probe, strongly suggested a partial gene deletion in the vWF genes in SI.
Identification of the Gene Defect in S1
A genomic library was prepared from size-selected partially digested SI DNA as detailed in Materials and Methods. From a positive clone, a 2.0-kb subclone (JB2000) was isolated and shown by restriction mapping and by use as a probe in Southern blotting to correspond to the novel 2.0-kb EcoRI fragment seen in the initial Southern blotting experiments. It was reasoned that this clone would contain the deletion in the patient's vWF gene. JB2000 was sequenced and the sequence was compared with that of A 1 lf4.2, the 4.2-kb cloned EcoRI fragment from the equivalent part of the normal vWF gene. A1 lf4.2 includes exons 41 and 42 of the pre-pro-vWF molecule46 (amino acids 2326 through 2360 and 2361 through 2429. respectively). The differences between the normal clone A 1 l f4.2 and JB2000 are shown in Fig  3. The major difference is a deletion of 2320 bp of normal sequence from JB2000 (nucleotides 1553 to 3872, inclusive, numbering from the 5' end of clone A1 lf4.2). This deletion includes the whole of exon 42. Between the deletion breakpoints in JB2000 are 182 bp of novel inserted sequence. To investigate the origin of the 182-bp insert seen in JB2000 between the deletion breakpoints and to exclude any possibility of it being an artifact, the PCR was used to amplify this sequence of the vWF gene in S1, his relatives, and normal individuals. Primers were prepared, after reference to the DNA sequences, to flank the deleted sequence, which would give an amplified fragment of 246 bp in S1. In the normal nondeleted vWF gene, a theoretical fragment of 2384 bp would be amplified. This should be clearly distinguishable from the smaller deleted gene fragment, but it was doubtful whether a fragment of this size would be efficiently amplified under the PCR conditions used. The 246 fragment was clearly seen in PCR-amplified DNA from S1 and his carrier relatives (see below), but was not detected in noncarriers and DNA from normal individuals (Fig 4) . Digestion of the PCR-amplified material from S1 and his relatives with Tag1 and Hinf I also gave the expected bands, deduced by analysis of the inserted DNA sequence, of 178 and 48 bp and 145 and 101 bp, respectively (results not shown). These results clearly show that the inserted 182-bp sequence is not an artifact. Detailed searches of DNA data banks (Genbank) failed to identify any significant homologies to stored sequences. However, PCR experiments using primers within the 5' and 3' ends of the inserted sequence have demonstratated the presence of the insert sequence in all normal human DNA tested (Bowen unpublished observations, May 1989). Restriction enzyme analysis and Southern blotting using the amplified insert sequence as a probe suggested a single copy of this sequence at a site presently unidentified.
Family Studies
S 1 is a member of a large family who we have reported on previo~sly.~' The family tree is shown in Fig 5, and available phenotypic data are reported in Table 1 . The parents of S1 (I15 and 1114) are related and, taken with the results of S1 in Table 1 , indicate that he has severe type 111 vWD as a result of inheriting the same gene for a form of autosomal recessive vWD from each parent. Multimeric analysis of vWFAg in S1 plasma showed a lack of all bands except for a single, faint, low mol wt band (Fig 5) . The significance of this band is uncertain, but it could represent a low level of truncated vWF subunits. Phenotypic data on the parents and other family members (except 1112, see below) was essentially normal, apart from a tendency for vWFAg levels to be lower than VIIIAg or VIIIC, eg, 115, IV2. Multimeric vWFAg profiles were normal (Fig 5) . A second member of the S1 kindred (1112) was also shown to have vWD, but in a milder form (vWFAg 3 U/dL). Multimeric analysis showed a prominent low mol wt band accompanied by very faint higher mol wt multimers (not visible in Fig 5) . ies described above using PCR to detect the novel 182-bp insert confirmed these carrier status results. Of the seven carriers, four had normal phenotypic results (IV4 data was unavailable), one (115) had slightly reduced levels of vWF, and one (1112) had moderate vWD (see above). Unfortunately, no members of the second generation of this kindred were available at the time of the DNA studies except I11 (who also died soon after this study was commenced). A clear anomaly exists between the phenotypic and clinical results of I112 and the remaining six carriers of the defective gene. It is clear that the patient has inherited the defective gene from his father (112). and one possibility is that he has also inherited a recessive vWD trait from his mother (111). anti-human vWFAg antiserum. The dots on certain family members refer t o carriers of the condition (see Fig 6) . Abbreviation: ND, not done. making 1112 a compound heterozygote for two recessive vWD traits. Analysis of DNA from I1 1 has, to date, failed to show any defect within the vWF gene, using the probes available for this study. VWF gene RFLP analysis of DNA from 111,112,1112, and I113 failed to show whether 1112 and I113 had inherited the same or different vWF genes from their mother (111). Had they inherited the same vWF gene, then it would be likely that the defect in 1112 was a result of a new mutation in the maternally derived gene combined with the partially deleted paternal gene.
DISCUSSION
Cloning of the vWF gene by several laborat~ries~'~ has resulted in a series of cDNA probes that may be used to study the inheritance and nature of the defects that cause vWD. Nine intragenic RFLPs have been and are being used in family studies. To date, vWF gene deletions have only been identified in vWD patients or their relatives with the most severe form of vWD (type I11 with no detectable vWF). Shelton-lnloes et allo reported complete vWF gene deletions in two homozygous cases with inhibitors to vWF, but in 17 patients with severe type I11 vWD without inhibitors no deletions were found. Ngo et all2 described both homozygous and heterozygous severe vWD with complete vWf gene deletions, but only the homozygous cases had inhibitors to vWF. In our study, six severe type I11 cases were examined, only one of whom (Sl) developed an inhibitor. Here again this was the only patient in which a deletion has been demonstrated. Previous studies in hemophilia B (factor IX deficiency) have also suggested a high prevalence of gene deletions in severe inhibitor patients:' although more recent studies suggest that large deletions occur in only about 50% of cases." In hemophilia A (factor VI11 deficiency) the figures are probably similar.
Our hypothesis that SI was homozygous for a vWF gene with a partial 3' end deletion was confirmed by the cloning and sequencing studies (clone JB2000). and direct comparison with a clone from the same area of the gene isolated from a normal DNA library. These results are summarized in Fig  7. The presence of exonic sequence in JB2000, later confirmed to be exon 41 of the vWF gene, identified the position of JB2000 within the vWF gene. Comparison with the normal clone A1 lf4.2, which includes exons 41 and 42. showed loss of 2320 bp of DNA from JB2000, including the whole of exon 42. Further analysis of exon-intron boundaries showed that this deletion not only removed exon 42, but any resultant splicing of exon 41 to exon 43 would result in a frame shift with in-frame stop codons in exon 43. This probably accounts for the fact that no vWFAg was detectable in SI plasma by sensitive ELISA. The presence of a transient truncated form of vWF subunit cannot be entirely ruled out, and may be represented by the faint band seen on multimer analysis (Fig 5) .
Analysis of the sequences flanking the breakpoints in JB2000 failed to show any consensus sequences. The only Alu repeat sequences were within the deleted DNA region, and there were no obvious features of normal sequence to explain the placement of the deletion boundaries. Much of the region of intron 40 sequenced in these experiments was highly repetitive, showing several areas of ATCT repeats. A comparison of JB2000 and X I lf4.2 showed a difference in length of one of these repeats (Fig 3) . The novel 182-bp sequence detected between the breakpoints in JB2000 was shown by PCR amplification combined with restriction enzyme analysis to be present in DNA extracted from S1 and his carrier relatives. Because the primers used for this PCR analysis were primers to normal vWF gene sequence flanking the deletion breakpoints and the size of the amplified fragment exactly matched that calculated from the JB2000 sequence data, it was concluded that these results showed the presence of the insertion within the deleted vWF gene in all those tested. This fragment was not seen after PCR amplification of noncarrier (as detected by the absence of the 2.0-kb EcoRI Southern blotting fragment) or normal DNA. The source or nature of this inserted sequence was examined by computer search of DNA databanks, but no significant matches were found. However, preliminary PCR and Southern blotting experiments in our laboratory using primers from within the insert sequence to amplify the insert sequence suggest that the sequence is present within the normal human genome at an unknown site. The SI kindred was previously reported by Bloom and Peake4' because of the unusual finding of two forms of vWD within the same family, with S1 (IV5 in Fig 5) having severe type 111 vWD and I112 moderate vWD. Phenotypic data would suggest that I112 probably has type I vWD. However, until this study, we were unable to be sure that both IV5 and I112 had inherited the same defective vWF gene. It is clear from the analysis reported here that I112 is a carrier of the defective vWF gene for which IV5 is homozygous, and therefore they do, at least in part, have the same defect. Although I112 clearly has vWD, the remaining six carriers of the defective gene within the family do not, or have a very mild form of it.
It is suggested that I112 is a compound heterozygote for the defective vWF gene and an as yet undetected second abnormality. This may have arisen spontaneously in the patient or, more likely, has been inherited from his mother (111, Fig 5) . Studies on her have failed to detect any abnormality at either the genotypic or phenotypic level. Therefore, she may be a carrier of a second type of recessive vWD for which, with present techniques, we are unable to detect any abnormality. Alternatively, a new mutation may have occurred in the maternally derived vWF gene in patient 1112.
If either of the above propositions is proven to be correct and I112 is a compound heterozygote for two distinct forms of vWD, then classification of his defect into the usual vWD system is of doubtful value. How many of the rare forms of vWD reported in the literature are similar to this is not known at present, but the possibility should be kept in mind when studying rare cases of vWD. Analysis of the vWF genes in the various types of vWD should eventually help to rationalize the present complex vWD classification.
